{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-303831","form_type":"8-K","ticker":"MIRM","cik":"0001759425","company_name":"Mirum Pharmaceuticals, Inc.","filed_at":"2022-12-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:52.008889+00:00","generated_at":"2026-06-21T05:34:39.071102+00:00","sec_items":["8.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Mirum receives EC approval for LIVMARLI in Alagille syndrome across EU","bullets":["European Commission granted marketing authorization for LIVMARLI (maralixibat) oral solution.","Indicated for cholestatic pruritus in Alagille syndrome patients aged 2 months and older.","First and only approved treatment for ALGS in both EU and US; ALGS affects 1 in 30,000 globally.","Approval follows positive CHMP opinion from September 2022.","Authorization covers all 27 EU member states for marketing."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-303831","json":"https://secwatch.observer/filing/0001193125-22-303831.json","markdown":"https://secwatch.observer/filing/0001193125-22-303831.md","text":"https://secwatch.observer/filing/0001193125-22-303831.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1759425/000119312522303831/0001193125-22-303831-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1759425/000119312522303831/d384957d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T05:34:39.071102+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}